New agents and regimens for diffuse large B cell lymphoma

• Main Authors: Liang Wang, Lin-rong Li, Ken H. Young
• Format: Article
• Language: English
• Published: BMC 2020-12-01
• Series: Journal of Hematology & Oncology
• Subjects: Diffuse large B cell lymphoma; Chimeric antigen receptor T cells; Immunotherapy; Chemoresistance; Novel agents; Genetic classification
• Online Access: https://doi.org/10.1186/s13045-020-01011-z

Abstract As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHOP and fare poorly. Unsatisfied outcomes for those relapsed/refractory patients prompted efforts to discover new treatment approaches for DLBCL, including chimeric antigen receptor T cells, bispecific T cell engagers, immunomodulatory drugs, immune checkpoint inhibitors, monoclonal antibodies, antibody–drug conjugates, molecular pathway inhibitors, and epigenetic-modifying drugs. Herein, up-to-date data about the most promising treatment approaches for DLBCL are recapitulated, and novel genetic classification systems are introduced to guide individualized treatment for DLBCL.